Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low dose CDT for acute pulmonary embolism
NCT03854266Phase 2Unknown
- Sponsor
- Aarhus University
- Start
- Mar 2020
- Primary completion
- Mar 2023
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tissue-plasminogen activator in pulmonary embolism (PE) (2 arms), sponsored by Aarhus University. Primary endpoint: Right ventricle to left ventricular diameter ratio at 24 hours. Status: unknown.
02
Drugs
tissue-plasminogen activator
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT03854266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03854266.